(Reuters) – The U.S. Food and Drug Administration on Friday extended for the second time its review of Amicus Therapeutics Inc’s experimental combination therapy to treat a rare genetic disorder that causes muscle impairment.
(This story has been refiled to remove extraneous characters in dateline)
(Reporting by Khushi Mandowara and Bhanvi Satija in Bengaluru; Editing by Sriraj Kalluvila and Devika Syamnath)
